Promise of factor Xa inhibition in acute coronary syndromes

Leong Lee, Derek Chew

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Drugs that inhibit factor Xa have been shown to reduce mortality and morbidity in acute coronary syndromes (ACS). Presently, factor Xa inhibition is most often achieved indirectly with the heparins and, increasingly, fondaparinux. Despite effective anticoagulation with indirect factor Xa inhibition there remains considerable mortality and morbidity in ACS. The recently developed direct factor Xa inhibitors (the xabans) appear to offer promise as alternatives to the heparins. We review the evidence behind indirect and direct factor Xa inhibition in non-ST-segment elevation ACS, ST-segment elevation myocardial infarction, and with percutaneous coronary intervention.

Original languageEnglish
Pages (from-to)40-48
Number of pages9
JournalCurrent Cardiology Reports
Volume14
Issue number1
DOIs
Publication statusPublished - 1 Feb 2012
Externally publishedYes

Keywords

  • Acute coronary syndrome
  • Apixaban
  • Enoxaparin
  • Factor Xa
  • Factor Xa inhibition
  • Fondaparinux
  • Heparin
  • Low molecular weight heparin
  • NSTEACS
  • NSTEMI
  • Otamixaban
  • Rivaroxaban
  • STEMI
  • Unfractionated heparin
  • Unstable angina

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this